Literature DB >> 1953398

Cumulative risks of developing extrapyramidal signs, psychosis, or myoclonus in the course of Alzheimer's disease.

J Y Chen1, Y Stern, M Sano, R Mayeux.   

Abstract

Cumulative risks of developing extrapyramidal signs, psychosis, and myoclonus in the course of Alzheimer's disease (AD) were estimated in 72 patients with probable AD by the Kaplan-Meier survival method. The cumulative risk functions were found to increase at different rates for different signs as AD progressed. Comparisons of the cumulative risk functions revealed that in the early stages of AD, extrapyramidal signs and psychosis were more likely to develop than myoclonus. As AD progressed, the risk of developing myoclonus became as great as that of developing the other two signs. This study suggests that extrapyramidal signs, psychosis, and myoclonus represent developmental features that mark the progression of AD, rather than indicators of disease subtypes. The estimated cumulative risk functions set a reasonable expectation for the timing and likelihood of the emergence of the clinical signs. This, in turn, might aid in disease prognosis because the biological bases of these signs have been established and they have been shown to be predictive of other markers of disease course.

Entities:  

Mesh:

Year:  1991        PMID: 1953398     DOI: 10.1001/archneur.1991.00530230049020

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  22 in total

1.  Familial associations of Alzheimer disease and essential tremor with Parkinson disease.

Authors:  S Costello; Y Bordelon; J Bronstein; B Ritz
Journal:  Eur J Neurol       Date:  2010-03-17       Impact factor: 6.089

2.  Incident Psychosis in Subjects With Mild Cognitive Impairment or Alzheimer's Disease.

Authors:  Elise A Weamer; Mary Ann A DeMichele-Sweet; Yona K Cloonan; Oscar L Lopez; Robert A Sweet
Journal:  J Clin Psychiatry       Date:  2016-12       Impact factor: 4.384

3.  Extrapyramidal signs before and after diagnosis of incident Alzheimer disease in a prospective population study.

Authors:  Florence Portet; Nikolaos Scarmeas; Stephanie Cosentino; Elisabeth P Helzner; Yaakov Stern
Journal:  Arch Neurol       Date:  2009-09

Review 4.  Epidemiology of the dementias: recent developments and new approaches.

Authors:  C M van Duijn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-05       Impact factor: 10.154

Review 5.  Epileptic activity in Alzheimer's disease: causes and clinical relevance.

Authors:  Keith A Vossel; Maria C Tartaglia; Haakon B Nygaard; Adam Z Zeman; Bruce L Miller
Journal:  Lancet Neurol       Date:  2017-04       Impact factor: 44.182

6.  Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: a de novo PSEN-1 mutation.

Authors:  Miryam Carecchio; Marina Picillo; Lorella Valletta; Antonio E Elia; Tobias B Haack; Autilia Cozzolino; Annalisa Vitale; Barbara Garavaglia; Arcangela Iuso; Caterina F Bagella; Sabina Pappatà; Paolo Barone; Holger Prokisch; Luigi Romito; Valeria Tiranti
Journal:  Neurogenetics       Date:  2017-06-29       Impact factor: 2.660

7.  Intra- and inter-cortical motor excitability in Alzheimer's disease.

Authors:  Jacqueline Hoeppner; Martin Wegrzyn; Johannes Thome; Alexandra Bauer; Imke Oltmann; Johannes Buchmann; Stefan Teipel
Journal:  J Neural Transm (Vienna)       Date:  2011-11-13       Impact factor: 3.575

8.  Clinicopathologic study of Alzheimer's disease: Alzheimer mimics.

Authors:  Yong S Shim; Catherine M Roe; Virginia D Buckles; John C Morris
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

9.  Motor signs during the course of Alzheimer disease.

Authors:  N Scarmeas; G M Hadjigeorgiou; A Papadimitriou; B Dubois; M Sarazin; J Brandt; M Albert; K Marder; K Bell; L S Honig; D Wegesin; Y Stern
Journal:  Neurology       Date:  2004-09-28       Impact factor: 9.910

10.  [Psychosis in elderly post-traumatic stress disorder patients].

Authors:  G Böwing; K U R Schmidt; G Juckel; S G Schröder
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.